Aspire Biopharma Holdings (ASBP) Short term Debt (2023 - 2026)

Aspire Biopharma Holdings (ASBP) has 4 years of Short term Debt data on file, last reported at $499214.0 in Q1 2026.

• On a quarterly basis, Short term Debt changed 0.0% year-over-year to $499214.0 in Q1 2026; TTM through Mar 2026 was $499214.0, a 0.0% change from a year earlier, with the FY2025 full-year figure at $1.3 million, down 64.33% from the prior year.
• Short term Debt for Q1 2026 stood at $499214.0, down from $1.3 million in the prior quarter.
• Over the last five years, Short term Debt for ASBP reached as high as $4.9 million in Q3 2024 and fell as low as $12384.0 in Q4 2023.
• Historically, Short term Debt has averaged $1.7 million across 4 years, with a median of $499214.0 in 2025.
• Across the five-year window, Short term Debt jumped 29111.14% in 2024 and slumped 64.33% in 2025, its largest moves.
• Year by year, Short term Debt stood at $12384.0 in 2023, then soared by 29111.14% to $3.6 million in 2024, then slumped by 64.33% to $1.3 million in 2025, then sank by 61.32% to $499214.0 in 2026.
• Per Business Quant data, the three most recent Short term Debt figures were $499214.0 in Q1 2026, $1.3 million in Q4 2025, and $4.7 million in Q3 2025.